
Jobs to go at Takeda as it shuts down Cambridge facility
pharmafile | August 26, 2016 | News story | Manufacturing and Production, Medical Communications | Cambridge, Jobs, Takeda, closure
Takeda has announced plans to close its facility in Cambridge in the UK, to refocus its research and development operations in Japan and the United States.
It is unclear, at this stage, what will happen to the jobs on site but fears have emerged that many of them may be lost. This closure forms part of the Japanese company’s plan to refocus its R&D efforts in oncology, gastroenterology and the central nervous system.
The company indicates that these measures taken are critical to provide the “necessary organisational and financial flexibility to drive innovation, enhance partnerships, and improve R&D productivity for long-term sustainable growth.” This restructure is set to cost Takeda around $725 million.
To fund these new ventures, Takeda plans to raise about $1 billion from sale of non-core assets, including Wako Pure Chemical.
All may not yet be lost for those employed by Takeda in Cambridge however, as Horizon CEO Darrin Disley encouraged those workers to come join his company. He says: “I would positively encourage applications from biologists who find themselves laid off.”
Sean Murray
Related Content

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …






